Role of Fetuin-A in Systemic Sclerosis-associated Calcinosis

REFERENCES

1. 1.↵
   1. Boulman N,
   2. Slobodin G,
   3. Rozenbaum M,
   4. Rosner I

   . Calcinosis in rheumatic diseases. Semin Arthritis Rheum 2005;34:805–12.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Schäfer C,
   2. Heiss A,
   3. Schwarz A,
   4. Westenfeld R,
   5. Ketteler M,
   6. Floege J,
   7. et al.

   The serum protein a2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003;112:357–66.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Lebreton JP,
   2. Joisel F,
   3. Raoult JP,
   4. Lannuzel B,
   5. Rogez JP,
   6. Humbert G

   . Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979;64:1118–29.

   OpenUrlPubMed
4. 4.↵
   1. Sulli A,
   2. Secchi ME,
   3. Pizzorni C,
   4. Cutolo M

   . Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis 2008;67:885–7.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Cozzolino M,
   2. Biondi ML,
   3. Galassi A,
   4. Gallieni M,
   5. d’Eril GV,
   6. Brancaccio D

   . Gene polymorphisms and serum alpha-2-Heremans-Schmid levels in Italian haemodialysis patients. Am J Nephrol 2007;27:639–42.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Fisher E,
   2. Stefan N,
   3. Saar K,
   4. Drogan D,
   5. Schulze MB,
   6. Fritsche A,
   7. et al.

   Association of AHSG gene polymorphisms with fetuin-A plasma levels and cardiovascular diseases in the EPIC-Potsdam study. Circ Cardiovasc Genet 2009;2:607–13.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Krieg T,
   2. Takehara K

   . Skin disease: a cardinal feature of systemic sclerosis. Rheumatology 2009;48 Suppl 3:iii14–8.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Wang XQ,
   2. Hayes MT,
   3. Kempf M,
   4. Fraser JF,
   5. Liu PY,
   6. Cuttle L,
   7. et al.

   Fetuin-A: a major fetal serum protein that promotes “wound closure” and scarless healing. J Invest Dermatol 2008;128:753–7.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Wigley FM

   . Vascular disease in scleroderma. Clin Rev Allergy Immunol 2009;36:150–75.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Caglar K,
    2. Yilmaz MI,
    3. Saglam M,
    4. Cakir E,
    5. Acikel C,
    6. Eyileten T,
    7. et al.

    Short-term treatment with sevelamer increases serum fetuin-A concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008;3:61–8.

    OpenUrlAbstract/FREE Full Text